DADmitriy Sergeevich Abramov

Dmitriy Sergeevich Abramov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitriy Sergeevich Abramov has a total of 329 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EVOLUTION OF THE DIAGNOSIS AND TREATMENT OF LYMPHOMAS IN CHILDREN IN THE RUSSIAN FEDERATION

    by N.V. Myakova, Yu.G. Abugova, V.V. Fominykh, D.A. Evstratov, D.S. Abramov, E.V. Volchkov, E.S. Romanenko, E.V. Samochatova, A.G. Rumyantsev

    The period from the mid-1980s to the present has been marked by significant progress in understanding the pathogenesis, diagnosis, and treatment of malignant lymphoproliferative diseases in children. Lymphomas — both Hodgkin's lymphoma and non-Hodgkin's lymphomas (NHL) — represent a significant proportion of childhood oncological diseases, accounting for 10% to 15% of all malignant neoplasms in individuals under 18 years of age. Improvements in chemotherapy protocols, the introduction of modern radiation diagnostic methods, the development of molecular genetic technologies, and the emergence of immunotherapeutic approaches have radically changed the prognosis of these diseases. While overall survival for NHL in children did not exceed 30–40% in the 1970s, by the early 2020s, 5-year survival rates for most histological variants of NHL reached 80–95%. This article focuses on the development of diagnostic and therapeutic approaches to the treatment of lymphomas in children in the Russian Federation over the past four decades.

  • Open Access

    Combined immune deficiency caused by a hypomorphic IL2RG variant and disguised as Burkitt leukemia: a clinical case

    by Alexey Yu. Merkushov, Меркушов Алексей Юрьевич, E. Ya. Musaeva, Мусаева Э. Я., D. Е. Pershin, Першин Д. Е., E. V. Raykina, Райкина Е. В., Yu. G. Abugova, Абугова Ю. Г., et al.

    X-linked severe combined immunodeficiency (X-SCID) is an inborn error of immunity characterized by almost total absence of T and NK cells with normal counts of functionally impaired B cells (T–B+NK–) that is caused by pathogenic variants in the IL2RG gene resulting in early onset of life-threatening infections. Hypomorphic X-SCIDs present with variable clinical features and are characterized by later onset of infectious complications, a wide range of autoimmune manifestations, and increased risk of malignancies. In this article, we report a rare case of atypical X-SCID presenting with partial red cell aplasia and Burkitt leukemia as the first signs of immune dysregulation. Verification of the diagnosis of X-SCID leads to a different treatment approach, including the use of hematopoetic stem cell transplantation as a curative option. It highlights the importance of awareness of inborn errors of immunity among hematologists and oncologists.

  • Open Access

    Molecular features of mature B-cell non-Hodgkin lymphomas in children

    by L. S. Filatova, E. V. Volchkov, A. S. Sharlai, D. S. Abramov, Y. G. Abugova, N. V. Myakova

    This article is a review of the current literature on the molecular and genetic features of mature B-cell non-Hodgkin lymphomas (B-NHL) in children. This group of lymphoproliferative neoplasms is characterized by relative similarity in morphological and immunophenotypic features while exhibiting pronounced heterogeneity at the molecular and genetic level. Recent studies have enabled the identification of distinct biological subtypes of B-NHL, which has significantly changed approaches to their diagnosis and treatment. Our review examines the classification features of B-NHL in children, as well as key molecular genetic abnormalities and oncogenic signaling pathways responsible for the development of this group of diseases. This article also highlights the need for pediatric-specific studies of B-NHL and the development of specialized diagnostic and therapeutic approaches is emphasized.

  • Open Access

    Treatment of lymphoblastic lymphomas in children in Russia: preliminary results of a multicenter retrospective study

    by E. V. Volchkov, T. Yu. Pavlova, G. I. Shestopalov, L. S. Zubarovskaya, A. V. Protsvetkina, E. A. Burtsev, D. S. Abramov, G. R. Kazaryan, V. V. Martynenko, K. A. Tsytsylina, et al.

    Background. Lymphoblastic lymphomas (LBL) are an aggressive variant of non-Hodgkin’s lymphomas (NHL), which ranks second in frequency among non-Hodgkin’s lymphomas in children. According to international data, the effectiveness of LBL therapy in children reaches 85 %. In Russia, information on the treatment results for this disease is extremely limited. Aim. To present preliminary data on the results of LBL therapy in children in Russia. Materials and methods. The study included 392 pediatric LBL patients, treated in 57 specialized hospitals of the Russian Federation from 1999 to 2024. Results. The overall and event-free survival rates were 83 % (95 % confidence interval 78–88) and 70 % (95 % confidence interval 64–78), respectively. In addition, the analysis revealed a high frequency of thrombotic complications (29 % of all patients), especially in cases of T-cell LBL. No significant differences in disease outcomes were found between tumor immunophenotypes, the type of asparaginase, and the stage of the disease. A separate analysis of the results of LBL therapy according to the ALL IC-BFM 2002 / 2009 protocols (146 patients) with stricter criteria for the response to induction therapy (tumor reduction of more than 70 %) and early chemotherapy intensification with high-dose blocks at the N. N. Blokhin National Medical Research Center of Oncology showed the event-free and overall survival of about 90 %. The Cox regression model of the dependence of therapy outcomes on residual tumor volume at the end of induction in the main cohort of patients did not reveal an association between residual tumor volume and overall survival (p = 0.2), but there was a statistical association with event-free survival (p = 0.006). Discussion. This paper presents preliminary data from the first multicenter study of LBL therapy in pediatric patients in the Russian Federation. According to our data, LBL survival rates in the Russia should be improved. An important problem in the treatment of LBL in children is therapy complications, especially the high incidence of thrombosis. In this regard, anticoagulant prophylaxis is recommended for patients with LBL, especially with the T-cell phenotype and the presence of risk factors. Further studies are also needed to identify high-risk patients for the development of new personalized therapy approaches. Conclusion. The paper presents preliminary results from the first multicenter clinical study of LBL therapy in children in Russia, indicating the necessity of treatment approaches improvement for increase a treatment effectiveness.

  • Open Access

    Features of diagnosis and management of patients with autoimmune lymphoproliferative syndrome caused by somatic defects of the FAS gene

    by Oksana A. Shvets, A. M. Kieva, A. A. Semchenkova, Z. A. Nesterenko, N. Yu. Kan, A. A. Moiseeva, D. V. Bogdanova, E. A. Deordieva, V. I. Burlakov, Zh. A. Kuzminova, et al.

    Introduction. Autoimmune lymphoproliferative syndrome (ALPS) is an inborn error of immunity with impaired FAS-mediated apoptosis. The disease responds well to therapy with the mTORC1-inhibitor sirolimus (SRL). The diagnosis of ALPS is based on the European Society for Immunodeficiencies (ESID) diagnostic criteria, which include the main clinical manifestations in combination mainly with an increased level of double-negative T-lymphocytes (DNT) with the CD3+TCRαβ+CD4–CD8–-phenotype. Most cases of ALPS are caused by germinal mutations in the FAS gene, however, somatic changes in this gene (ALPS-sFAS) can be detected in 15–20% of patients. Aim: to analyze the diagnostic features and clinical presentation before and during SRL treatment in patients with ALPS-sFAS. Materials and methods. In our cohort of patients (n = 6), we analyzed main clinical data (clinical presentation, laboratory and instrumental data), the stages of genetic search and response to SRL therapy. We observed an early onset of the disease (median of 1.7 years), with delayed clinical (median of 3.7 years) and genetic (median of 6.2 years) diagnosis. Results. At the initial examination, only 67% of the patients met the ESID criteria. In 50% of cases with DNT levels 9.9%, somatic mutations in the FAS gene were detected in whole blood DNA, in other cases, we analyzed DNA from sorted DNT cells. All of our patients had previously undescribed somatic mutations in the FAS gene. Our experience of SRL treatment in patients with ALPS-sFAS has been more than 10 years. We observed a good clinical response, as well as continued remission of the disease at a reduced dose of SRL (1.5 mg/m2). In 67% of cases, various adverse events were observed when the SRL dose was 1.5 mg/m2. Conclusion. The obtained results demonstrate the complexity of diagnosis and the need for concern regarding ALPS-cFAS, taking into account the effectiveness of pathogenetic therapy, as well as the importance of a personalized approach in molecular genetic verification of the diagnosis.

  • Open Access

    Systemic toxoplasmosis with central nervous system involvement in children following hematopoietic stem cell transplantation: a case series

    by Sergey L. Blagov, Igor Gennadjevich Khamin, Larisa Shelikhova, Vladislav Pavlovich Bondarenko, G. V. Tereshchenko, Denis Sergeevich Lunev, Galina Gennadjevna Solopova, Dmitriy Sergeevich Abramov, Alexey Aleksandrovich Maschan, Michael Aleksandrovich Maschan, et al.

    Until the recovery of adaptive immunity, recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at an increased risk of severe or even fatal infections. One such example is toxoplasmosis – a rare but an extremely dangerous complication in immunocompromised patients. The probability of Toxoplasma gondii reactivation after allo-HSCT is low and depends primarily on the serologic status of the donor and the recipient. Here, using as an example 4 clinical cases of cerebral toxoplasmosis in children after allo-HSCT, we want to emphasize the importance of timely and comprehensive testing, prevention and treatment of this complication in allo-HSCT patients.

  • An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

    by A.S. Sharlai, E.V. Volchkov, D.S. Abramov, I.V. Sidorov, M.A. Baranova, N.V. Myakova, D.M. Konovalov

    Objective. To improve the stratification algorithm for aggressive B-cell lymphomas in children based on the analysis of genetic changes in the genes TP53, MYC, BCL2, BCL6 and the long arm of chromosome 11 (11q). Material and methods. A comprehensive cytogenetic and molecular genetic analysis of tumor samples was carried out using NGS and FISH methods. Rearrangements of the MYC locus and the presence of translocations with different chromosomal partners were investigated, as well as the analysis of mutations and deletions of the TP53 gene. The presence of MYC, BCL2, BCL6 rearrangements and 11q aberrations was investigated as part of the algorithm. Results. It has been shown that the classical translocation, t(8;14)(q24;q32) MYC::IGH, is detected in 77% of cases with typical Burkitt lymphoma histology. This translocation was not present in 23% of the samples. In a group of cases with classic histology of Burkitt lymphoma, where the t(8;14)(q24;q32) translocation was absent, rare genetic variations were identified — 11q gain/loss, and atypical FISH patterns indicative of complex genetic changes. TP53 mutations were detected in 26-30% of cases, localized mainly in the DNA-binding domain. A wide range of genetic changes has been identified, including monoallelic TP53 deletions and atypical FISH patterns that require attention and additional research. Conclusion. An improved diagnostic algorithm based on the combined use of FISH and NGS methods makes it possible to increase the accuracy of identification of genetic subtypes of aggressive B-cell lymphomas in children. This helps to categorize the diagnosis based on the molecular and genetic characteristics of the tumor, paving the way for improved prognosis and treatment effectiveness.


  • Open Access

    Disseminated Kaposi's sarcoma in a child treated with allogeneic hematopoietic stem cell transplantation

    by Mikhail A. Lemeshev, Anna P. Vasilieva, Svetlana A. Radygina, Dmitry S. Abramov, Lili A. Khachatryan, Zalina A. Abashidze, Svetlana N. Kozlovskaya, Yulia V. Skvortsova, Dmitry N. Balashov, Alexey A. Maschan, et al.

    Kaposi's sarcoma (KS) is a rare complication of hematopoietic stem cell transplantation (HSCT). Here, we report a case of disseminated KS in a pediatric patient after haploidentical HSCT that developed during secondary immunosuppression. Treatment with liposomal doxorubicin resulted in a complete metabolic response. This case highlights the importance of early diagnosis and stresses the need to consider KS in the differential diagnosis of cutaneous and systemic manifestations in patients following HSCT. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.

  • Open Access

    Extramedullary Relapse of CBFA2T3::GLIS2-Positive Megakaryoblastic Leukemia Mimicking Secondary Ewing Sarcoma: An Exemplary Case for the Diagnostic Trap

    by Svetlana Lebedeva, Ekaterina Mikhailova, Sophia Bogacheva, Dmitry Abramov, Svetlana Kashpor, Alexander Druy, Alexandra Semchenkova, Marina Gaskova, Olga Lotonina, Ilya Sidorov, et al.

    In children without Down syndrome who have acute megakaryoblastic leukemia (AMKL), inv(16)(p13q24)/CBFA2T3::GLIS2 is the most frequent genetic aberration. Pediatric CBFA2T3::GLIS2-positive AMKL is strongly associated with a poor prognosis and a high cumulative incidence of relapse. One of the key laboratory signs of CBFA2T3::GLIS2-positive AMKL is the RAM immunophenotype, which looks very similar to that of solid-tumor bone marrow (BM) infiltration. For this reason, in cases of isolated extramedullary involvement of CBFA2T3::GLIS2-positive AMKL, excluding solid tumors may be challenging. We report a case of a girl with isolated extramedullary CBFA2T3::GLIS2-positive AMKL relapse, which was misdiagnosed as secondary Ewing sarcoma. The morphological differential diagnosis between Ewing sarcoma and AMKL presented significant challenges owing to their overlapping histological features (small, round blue-cell morphology and similar growth patterns). The tumor cells’ immunophenotype completely mirrored that at the initial diagnosis of AMKL. Additional cytogenetic and molecular studies confirmed the presence of the CBFA2T3::GLIS2 fusion, but no Ewing sarcoma-specific EWSR1, FUS and CIC fusion transcripts were found. Thus, extramedullary CBFA2T3::GLIS2-positive AMKL relapse was confirmed. The presented case demonstrates the difficulties in differential diagnosis between AMKL relapse and the development of a secondary tumor.


  • Open Access

    Extramedullary Relapse of CBFA2T3::GLIS2-Positive Megakaryoblastic Leukemia Mimicking Secondary Ewing Sarcoma: An Exemplary Case for the Diagnostic Trap

    by Svetlana Lebedeva, Ekaterina Mikhailova, Sophia Bogacheva, Dmitry Abramov, Svetlana Kashpor, Alexander Druy, Alexandra Semchenkova, Marina Gaskova, Olga Lotonina, Ilya Sidorov, et al.

    Acute megakaryoblastic leukemia (AMKL) is a heterogeneous form of acute myeloid leukemia (AML) and is significantly more common in children than in adults. In non-Down syndrome children with AMKL, inv(16)(p13q24)/CBFA2T3::GLIS2 is the most frequent genetic aberration. Pediatric CBFA2T3::GLIS2-positive AMKL is strongly associated with a poor prognosis and a high cumulative incidence of relapse. One of the key laboratory signs of CBFA2T3::GLIS2-positive AMKL is the RAM immunophenotype, which includes dim to negative CD45 and CD38 expression, extremely bright CD56 and a lack of HLA-DR on leukemic cells. This immunophenotype looks very similar to that of solid tumor bone marrow (BM) infiltration. For this reason, in cases of isolated extramedullary involvement of CBFA2T3::GLIS2-positive AMKL, excluding solid tumors may be challenging. The differential diagnosis between extramedullary AMKL relapse and secondary tumors is especially difficult. We report a case of a 3.5-year-old girl with isolated extramedullary CBFA2T3::GLIS2-positive AMKL relapse, which was misdiagnosed as secondary Ewing sarcoma. The morphological differential diagnosis between Ewing sarcoma and AMKL presents significant challenges owing to their overlapping histological features (small round blue cell morphology and similar growth patterns). The tumor cells immunophenotype was completely mirrored that at the initial diagnosis of AMKL. Additional cytogenetic and molecular studies confirmed the presence of the CBFA2T3::GLIS2 fusion, but no Ewing sarcoma-specific EWSR1 fusion transcripts were found. Thus, extramedullary CBFA2T3::GLIS2-positive AMKL relapse was confirmed. The patient’s clinical condition gradually worsened, and the patient died 5 months after diagnosis. The presented case demonstrates difficulties in the differential diagnosis between AMKL relapse and the development of a secondary tumor.